College of Medicine

- Admissions Overview
- - MD Program
    UNMC's rigorous academics, diverse clinical experiences and supportive environment put you on the path to becoming a skilled, compassionate physician.
  - How to Apply
    UNMC prepares medical degree students to meet the needs of patients through clinical practice, biomedical science and research, problem-solving and compassion.
  - Contact Us
    Review contact information for the Office of Admissions and Student Affairs in the College of Medicine at UNMC.
  - Verification and State Licensure
    Review opportunities for state licensure following completion of the MD program in the College of Medicine at UNMC.
- - MD-MBA Program
    A combined MD-MBA degree equips you with the tools you need to become highly skilled in both management and medicine.
  - MD-MPH Program
    Pursue your passion for public health and medicine with a combined MD-MPH and help solve complex health problems.
  - MD-PhD Program
    Do you have a passion for caring for patients and for research? Consider the dual MD-PhD degree.
- Education Overview
- - Curriculum
    Our curriculum produces physicians whose foundation in basic, clinical, and health systems sciences prepare them to promote health and reduce patient suffering.
  - Graduation Requirements
    Review requirements for students pursuing an MD at the UNMC College of Medicine to graduate and receive their degree.
  - Objectives
    The objectives of UNMC's medical degree program are to prepare you for success in primary care or specialty fields.
  - Service Learning
    Active participation in community service provides critical opportunities to apply skills and knowledge gained in medical school and develop a sense of empathy.
- - Enhanced Medical Education
    Enhanced Medical Education Tracks offer medical students an opportunity to perform an in-depth study of an interdisciplinary field of medicine.
  - Enhanced Medical Education Tracks
    EMET applicants are selected for Tracks based on their interest in the topic and motivation to complete work above and beyond the primary MD curriculum.
  - MD Honor’s Thesis Program
    The MD honors thesis encourages students to engage in scientific research during medical education and become eligible to graduate with honors.
- Research Overview
- Internal Grants
  The College of Medicine has a variety of research-related grant and award opportunities available to UNMC faculty.
- Comparative Effectiveness Research
  The Comparative Effectiveness Research (CER) program identifies knowledge gaps in the effectiveness of clinical care and improves CER in these areas.
- Great Plains IDeA-CTR
  The Great Plains IDeA-CTR is a collaborative effort between nine regional institutions that provides training, resources. and funding to regional researchers.
- Research and Development Committee
  The Research and Development Committee handles funding opportunities for faculty, including the Bridge Funding program, and student research opportunities.
- Student Opportunities
  The College of Medicine provides a variety of research opportunities for both current and prospective UNMC students.
- Residencies & Fellowships Overview
- Graduate Medical Education Programs
  UNMC's dozens of programs--including nearly 20 in internal medicine--allow residents and fellows a variety of specialties.
- House Officer Resources
  Find information for residents and fellows, including salaries, benefits and nearby housing.
- House Officer Wellness
  Wellness resources for residents and fellows include an assistance program and a private wellness lounge.
- Research
  We aim to facilitate house officers’ involvement in research in the areas of patient safety, quality improvement, healthcare disparities and education research.
- Salary and Benefits
  Paid vacation and professional leave, health insurance and meal allowances are just a few of the benefits residents receive in addition to their yearly salary.
- Contact Us
  Reach out to the Graduate Medical Education office for information about benefits, contracts, orientation or graduation.
Departments

— College of Medicine — Department of Internal Medicine — Divisions — Infectious Diseases — Antimicrobial Stewardship Program — Protected Antimicrobials — Fecal Microbiota (Rebyota)

Fecal Microbiota (Rebyota)

The Pharmacy and Therapeutics Committee approved the addition of Fecal Microbiota (Rebyota) to the formulary in March 2023 with use restricted to outpatient clinics and the infusion center only for Clostridioides difficile infection prophylaxis.

Efficacy

The primary efficacy analysis of the Phase 3 double blind, RCT (Randomized Controlled Trial), placebo-controlled study 2017-01 (PUNCH CD3) met the second pre-specified statistical success threshold 0.9750 but did not meet the more stringent 0.9993 first specified success threshold.

Prior to performing the analysis, the FDA (Food and Drug Administration) concluded that a posterior finding equivalent to meeting the first specified success threshold would be sufficient to demonstrate substantial evidence of effectiveness.

After the primary efficacy analysis only met the second specified success criteria, FDA considered whether the data from the study, as well as the data from the supportive clinical trials would be sufficient to demonstrate substantial evidence of effectiveness. Most FDA committee members thought the clinical data were adequate to support effectiveness of the product. The review team concluded that the data submitted demonstrates substantial evidence of effectiveness for the prevention of recurrent CDI (Clostridioides Difficile Infection) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI.

Safety

Rebyota is manufactured from human fecal matter donated by qualified individuals. The donors and donated stool are screened for transmissible pathogens; however, there may still be a risk of transmitting infectious agents. Additionally, it is possible that Rebyota may contain food allergens; the potential for adverse reactions due to food allergens is unknown.

Uniqueness

Rebyota is the first fecal transplant therapy for recurrent CDI approved by FDA. This therapy is approved for prophylaxis and is not considered for treatment of CDI.

Click for additional information about Rebyota